Mechanistic and Structural Understanding of Uncompetitive Inhibitors of Caspase-6

Christopher E. Heise1*, Jeremy Murray2, Katherine E. Augustyn3, Brandon Bravo1, Preeti Chugha3, Frederick Cohen4, Anthony M. Giannetti1, Paul Gibbons4, Rami N. Hannoush5, Brian R. Hearn3, Priyadarshini Jaishankar3, Cuong Q. Ly4, Kinjalkumar Shah1, Karen Stanger5, Micah Steffek2, Yinyan Tang3, Xianrui Zhao4, Joseph W. Lewcock6, Adam R. Renslo3, John Flygare4, Michelle R. Arkin3*

1 Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, California, United States of America, 2 Department of Structural Biology, Genentech, Inc., South San Francisco, California, United States of America, 3 Small Molecule Discovery Center, University of California San Francisco, San Francisco, California, United States of America, 4 Department of Discovery Chemistry, Genentech, Inc., South San Francisco, California, United States of America, 5 Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California, United States of America, 6 Department of Neuroscience, Genentech, Inc., South San Francisco, California, United States of America

Abstract

Inhibition of caspase-6 is a potential therapeutic strategy for some neurodegenerative diseases, but it has been difficult to develop selective inhibitors against caspases. We report the discovery and characterization of a potent inhibitor of caspase-6 that acts by an uncompetitive binding mode that is an unprecedented mechanism of inhibition against this target class. Biochemical assays demonstrate that, while exquisitely selective for caspase-6 over caspase-3 and -7, the compound’s inhibitory activity is also dependent on the amino acid sequence and P1’ character of the peptide substrate. The crystal structure of the ternary complex of caspase-6, substrate-mimetic and an 11 nM inhibitor reveals the molecular basis of inhibition. The general strategy to develop uncompetitive inhibitors together with the unique mechanism described herein provides a rationale for engineering caspase selectivity.

Introduction

Caspases are a family of cysteine proteases that are key mediators of apoptosis and inflammation [1,2]. The apoptotic “executioner” caspases (caspase-3, -6 and -7) are translated as proenzymes containing a short pro-domain, a p20 subunit, a linker region, and p10 subunit. Their canonical activation mechanism involves proteolysis by “initiator” caspases (caspase-8 and -9) at three distinct sites to remove the prodomain and linker region [3–6]. The resulting active enzyme is a dimer, wherein each subunit contains a p10 and p20 chain and one active site. The caspase enzymatic mechanism is similar to other cysteine proteases; substrate binds to the active site to form the Michaelis complex, a covalent tetrahedral intermediate is formed by attack of the active-site thiolate cysteine on the scissile carbonyl, the substrate amide bond is cleaved to generate an acyl enzyme intermediate, and the intermediate is hydrolyzed by water to yield the new substrate C-terminus and apo-enzyme [7]. Active caspases are capable of cleaving numerous cellular proteins [8,9] and carrying out the terminal phase of cell death signaling.

Due to the role of caspase-6 in neurodegeneration [10–14], there is strong interest in developing selective, small-molecule inhibitors of this enzyme. This family of proteases has proven resistant to traditional methods of drug discovery, however, and most known inhibitors contain a covalent warhead, significant peptidic character, and/or an aspartic acid. Each of these characteristics reduces the potential for caspase selectivity, cell permeability, and blood-brain barrier penetration. For instance, the traditional caspase probes used in biological assays are tetrapeptides containing the ideal substrate sequences for each caspase and a covalent warhead that reversibly or irreversibly modifies the active-site cysteine. These tools lack the necessary caspase selectivity profiles to facilitate the delineation of isoform-specific signaling pathways in a cellular context [15]. To address these challenges, a number of alternative chemical approaches have been used. Leyva, et al, recently disclosed the design of novel, nonpeptidic inhibitors identified through “substrate assisted screening”; while potent, these compounds are non-selective and still contain an irreversible covalent warhead [16]. There has also been significant interest in developing noncompetitive or allosteric inhibitors, with the idea that non-active site binding could achieve greater selectivity and improved physicochemical properties over competitive inhibitors [17,18]. This notion is supported by the discovery of an allosteric site at the dimer interface of caspases 1, 3, and 7. Applying the disulfide-trapping (Tethering) method of fragment discovery, scientists at Sunesis Pharmaceuticals identified fragments that bound at the dimer interface and inhibited enzymatic activity [19,20]. These fragments were not tested for...
caspase-6 inhibitors. The endpoint fluorescent emission (RFU) in each well was plotted as a function of inhibitor concentration and the 50% inhibition (IC50) values were determined using a nonlinear least squares fit of the data to a four parameter equation using Prism 5.0 software (GraphPad Software, San Diego, CA). Ki values for VEID-CHO were calculated using this equation: 

\[
Ki = \frac{IC50/\left[S\right]}{Km + \left[S\right]}
\]

Ki values for Compound 3 were calculated using this equation: 

\[
Ki = \frac{IC50/\left[S\right]}{Km + \left[S\right] + 1}
\]

Concentration-response curves for each inhibitor were normalized to zero and 100% based on no enzyme or DMSO control, respectively. For steady-state kinetic analysis, initial reaction velocity (RFU/minute) was plotted against substrate concentration at each inhibitor concentration and the data was fit to a hyperbolic Michaelis-Menten model using Prism 5.0 software. Km (\(\mu M\)) and Vmax (RFU/minute) were calculated by using this equation: 

\[
v = \frac{Vmax \cdot [S]}{Km + [S]}
\]

where \(v\) = initial reaction velocity at indicated substrate concentration (S). Vmax values were normalized to zero and 100% based on no enzyme or DMSO control, respectively.

**Chemical syntheses.** The synthesis of uncompetitive caspase-6 inhibitors is described in Experimental Procedures S1.

**Crystalization.** Crystals of a binary enzyme-substrate (zVEID) complex were first generated by reacting active caspase-6 with a 1.5 molar excess of a benzoyloxycarbonyl-VEID (zVEID) substrate possessing a 2,3,5,6-tetrafluorophenoxy leaving group for 4 hours. The reaction mixture was desalted and then concentrated to 6.5 mg/mL and crystallized in 12% (w/v) PEG3350, 0.2 M NaMalonate pH 4.0. Crystals of the binary complex of caspase-6/VEID were then soaked overnight with 1 mM of 3.

**X-ray data collection, structure determination and refinement.** Diffraction data to 2.0Å resolution was collected at Advanced Photon Source beamline 21-ID-G (Table S4). The data was indexed, integrated and scaled using HKL2000 [21] the structure was solved by molecular replacement using the Casp6-zVEID structure as the search model (PDB-ID 3OD5). The initial FoFc electron density maps clearly show unambiguous density for 3 bound close to the VEID peptide in both active sites (PDB-ID 4HVA). The compound was fit to the density and the model was subjected to iterative cycles of refinement and rebuilding using Phenix and Coot [22,23] (Table S4).

**Surface Plasmon Resonance**

For SPR experiments, caspase-6 was cloned to include a C-terminal avi-tag (Avidity) and expressed and purified as above, except that biotin ligase (BirA) was co-expressed and purified for fermentation. This resulted in an active caspase-6 protein with a single biotin molecule attached to the lysine in the avi-tag sequence. Avi-tagged zymogen C163A-caspase-6 was processed to mature C163A-caspase-6 by the addition of active caspase-3 and caspase-6. Chip preparation for neutravidin-based capture was performed as previously described using either a Biacore T100 or Biacore 3000 instrument (GE Healthcare) [24]. Running buffer was 50 mM HEPES pH 7.2, 100 mM MgSO4, 30 mM NaCl, 1 mM TCEP, 0.01% Triton X-100, 1% PEG-3350, 2.5% DMSO, and the instrument was set for 20 degrees C. After capture of one flow cell of apo-caspase-6 was exposed to a continuous flow of 20 \(\mu M\) VEID-FMK. A rise in signal could be detected for the binding/reacting of the VEID-FMK and exposure was continued until no additional rise in response was observed (~45 minutes) indicating full saturation of all binding sites. There was no observed decrease in signal upon washing, indicating the reaction was irreversible. Data were reduced, solvent corrected, double referenced, and fit using the Scrubber II software package.

**Experimental Procedures**

**Expression and Purification of Caspase-6**

Cloning, expression, and purification of caspase-6 for enzymatic assays is described in Experimental Procedures S1.

**Caspase Enzymatic Assays**

The in vitro enzymatic caspase assays utilize synthetic tetrapeptide substrates labeled with the fluorophores Rhodamine110 (R110) or 7-amino-4-methylcoumarin (AMC) at the P1 aspartic acid (Asp) residue. All assays were performed in 384-well plates in 12 \(\mu L\) reaction volume consisting of enzyme, substrate and indicated concentration of inhibitor or DMSO in assay buffer (50 mM HEPES [pH 7.0], 25 mM MgSO4, 0.5 mM EGTA, 5 mM Glutathione [GSH], 0.01% Triton X-100 containing 0.1% Bovine Gamma Globulin [BGG]). All inhibitors were serially diluted in 100% DMSO prior to dilution in assay buffer and transfer to assay plate. DMSO was diluted into assay buffer similarly for blank wells (no enzyme or compound) and final DMSO concentration was 1%. The concentration of caspase-6 used in enzymatic reactions typically varied between 1-10 nM depending on substrate used. Unless otherwise indicated, substrate concentration was within 3-fold of the determined Km. 5 \(\mu M\) (Ac-VEID)\(_2\)R110 \([Km_{app} = 8 \mu M]\); 5 \(\mu M\) (Ac-DEVD)\(_2\)R110 \([Km_{app} = 8 \mu M]\); 25 \(\mu M\) (Ac-IETD) \([Km_{app} = 70 \mu M]\); 25 \(\mu M\) (Ac-WEHD)\(_2\)R110 \([Km_{app} = 70 \mu M]\); 10 \(\mu M\) Ac-VEID-AMC \([Km_{app} = 16 \mu M]\); 5 \(\mu M\) Ac-VEID-R110 \([Km_{app} = 0 \mu M]\). The concentration of substrate utilized in selectivity assays for each caspase isoform was also held as close to Km\(_{app}\) as reasonably achievable (Table S1). Caspases-3 and -7 were expressed and purified at Genentech as the catalytic domain consisting of large p20 and small p10 subunits without the terminal avi-tag (Avidity) and expressed and purified as above, depending on substrate used. Unless otherwise indicated, substrate concentration was within 3-fold of the determined Km\(_{app}\). 5 \(\mu M\) (Ac-VEID)\(_2\)R110 \([Km_{app} = 0 \mu M]\); 5 \(\mu M\) (Ac-DEVD)\(_2\)R110 \([Km_{app} = 0 \mu M]\); 25 \(\mu M\) (Ac-IETD) \([Km_{app} = 0 \mu M]\); 10 \(\mu M\) Ac-VEID-AMC \([Km_{app} = 0 \mu M]\); 5 \(\mu M\) Ac-VEID-R110 \([Km_{app} = 0 \mu M]\).
Molecular Modeling

Modeling of 3 bound to the Michaelis complex and to the acyl
enzyme intermediate formed by VEID-R110/caspase-6 is de-
scribed in Experimental Procedures S1.

Results

Chemical Optimization of Screening Hits Yields Low
Nanomolar Inhibitors

We developed and ran a screening assay that monitored
inhibition of caspase-6 using a caged fluorophore substrate
(Figure 1A). The substrate contained a Rhodamine110 (R110)
dye conjugated to two valine-glutamate-isoleucine-aspartate
(VEID) tetrapeptides; cleavage of both peptides from the dye
yields maximal fluorescence. The original N-furoyl-phenylalanine
screening hit (compound 2) had undetermined stereochemical
configuration and exhibited modest inhibition of caspase-6
(IC50 = 20 μM). Synthesis of authentic samples of both R and S
enantiomers revealed that the R enantiomer, derived from the
unnatural D-phenylalanine, was approximately 100-fold more
potent than the S enantiomer. Based on potency and physico-
chemical properties, we selected compound 2 as a starting point
for chemistry (manuscript in preparation). From this effort, we
identified compound 3 with a potency of 11 nM (Figure 2).
Compound 3 contains four changes that led to improved potency
– use of the D-enantiomer at the amino acid, reduction of the acid
to an alcohol, removal of the methyl group from the central furan
ring, and addition of a meta-cyano substituent on the phenylala-
nine ring. Impressively, potency was increased 1,000-fold relative
to the original hit 2 without an increase in molecular weight,
resulting in a gain in the binding efficiency index (BEI; defined as
pIC50/molecular weight) [25] from 11.5 to 19.7).

Compound 3 Selectively Inhibits Caspase-6

To determine whether compound 3 was selective for caspase-6
relative to the other executioner caspases, we monitored the
activity of caspases-3 and -7 using divalent tetrapeptide R110
substrates containing the DEVD consensus cleavage site. Com-

pounds 3 possesses near absolute selectivity for inhibition of
caspase-6 cleavage of (VEID)2R110 compared to the other caspase
family members (Figure 1B; Table S2). Similar selectivity
profiles were observed for all compounds from this series tested in
this manner. By contrast, a peptidic caspase inhibitor with
aldehyde functionality (VEID-CHO) shows <35-fold selectivity
across the three caspases (Figure 1C; Table S2).

Compounds Possess Uncompetitive Mechanism of
Inhibition

We performed kinetic assays and determined the mechanism of
inhibition (MOI) of compound 3. As seen in Figure 3A and Figure
S1, increasing concentrations of compound 3 resulted in de-
creasing Km values as well as a concomitant decrease in the Vmax
(Table S3), indicative of an uncompetitive mechanism of in-
hibition. Thus, compound 3 binds to, and inhibits, the enzyme-
substrate complex. The pharmacological significance of uncom-
petitive inhibition is that compound potency is enhanced as the
substrate concentration in the reaction is increased (Figure 3B).

Compound 3 Prefers VEID-based Peptide Substrates

Given the preferential binding of these inhibitors to a substrate/
caspase-6 complex, we measured the inhibitory activity of 3
against a panel of related R110 substrates with alternative amino
acid sequences. Because potency of uncompetitive inhibitors is
dependent on the substrate concentration, care was taken for each
assay to ensure substrate was included at concentrations approx-
imating the measured $K_{m\text{app}}$ (see Experimental Procedures). The inhibitory activity of 3 was very sensitive to the peptide substrate used to measure caspase-6 activity. For example, when caspase-6 activity was measured using (DEVD)$_2$R110, the IC$_{50}$ of compound 3 was 481 nM, ~44-fold weaker than when monitored with (VEID)$_2$R110 substrate (Figure 4A). Other substrates render 3 even less effective; (IETD)$_2$R110 is inhibited only in the 100 µM range, where (WEHD)$_2$R110 is not inhibited by 3 up to 100 µM. Similar shifts in potency upon transition from (VEID)$_2$R110 to (DEVD)$_2$R110 were observed with numerous other compounds from this series and is likely independent of $K_m$ disparity as both substrates possess near identical $K_{m\text{app}}$ values. Further, the MOI of 3 as determined by Michaelis-Menten kinetics with (DEVD)$_2$R110 substrate is also uncompetitive in nature (Figure S2A). While this compound inhibits caspase-6 cleavage of VEID or DEVD based substrates (albeit with varying potency), it is incapable of inhibiting caspase-3 cleavage of (VEID)$_2$R110 (Figure 1B; Table S2). This suggests that the enzyme component in the enzyme/substrate complex confers a greater degree of selective binding than does the substrate component. In contrast, VEID-CHO equipotently inhibits caspase-3 cleavage of either substrate as would be expected for a competitive inhibitor (Figure 1C; Table S2).

To further investigate this unusual substrate-dependent behavior, we prepared monovalent VEID-R110 substrate, in which only one of the R110 amines is acylated with tetrapeptide. This substrate is inhibited by 3 as potently as the divalent (VEID)$_2$R110, the IC$_{50}$ of compound 3 was 481 nM, ~44-fold weaker than when monitored with (VEID)$_2$R110 substrate (Figure 4A). Other substrates render 3 even less effective; (IETD)$_2$R110 is inhibited only in the 100 µM range, where (WEHD)$_2$R110 is not inhibited by 3 up to 100 µM. Similar shifts in potency upon transition from (VEID)$_2$R110 to (DEVD)$_2$R110 were observed with numerous other compounds from this series and is likely independent of $K_m$ disparity as both substrates possess near identical $K_{m\text{app}}$ values. Further, the MOI of 3 as determined by Michaelis-Menten kinetics with (DEVD)$_2$R110 substrate is also uncompetitive in nature (Figure S2A). While this compound inhibits caspase-6 cleavage of VEID or DEVD based substrates (albeit with varying potency), it is incapable of inhibiting caspase-3 cleavage of (VEID)$_2$R110 (Figure 1B; Table S2). This suggests that the enzyme component in the enzyme/substrate complex confers a greater degree of selective binding than does the substrate component. In contrast, VEID-CHO equipotently inhibits caspase-3 cleavage of either substrate as would be expected for a competitive inhibitor (Figure 1C; Table S2).

To further investigate this unusual substrate-dependent behavior, we prepared monovalent VEID-R110 substrate, in which only one of the R110 amines is acylated with tetrapeptide. This substrate is inhibited by 3 as potently as the divalent (VEID)$_2$R110, thus the second peptide plays no role in determining the potency of 3 (Figure 4B). On the other hand, the dye does play a strong role. VEID-AMC, in which the R110 is replaced by amino-methyl coumarin, is inhibited by 3 with an IC$_{50}$ of 14 µM (~750-fold loss in potency). Despite the marked loss in potency of this compound when AMC fluorophore is present in the substrate, the MOI as defined by Michaelis-Menten kinetics for these two monovalent substrates also supports an uncompetitive mechanism of inhibition (Figure S2B and unpublished results). In summary, inhibition of peptide/caspase-6 by these compounds is dependent on the sequence of the tetrapeptide on the N-side and the dye on the C-side (prime-side) of the scissile bond, but the MOI is consistently uncompetitive.

The sensitivity of compound 3 to different peptide substrates prompted us to explore caspase-6-dependent proteolysis of a biologically relevant full-length protein substrate containing the VEID cleavage motif. Lamin A is a nuclear envelope protein possessing two globular domains separated by a helical rod containing a VEID sequence known to be the site of caspase-6 proteolysis [26,27]. Caspase-dependent digestion of recombinant Lamin A into two subunits is monitored via electrophoretic separation. As a positive control, Ac-VEID-CHO prevents 100% of cleavage at a concentration of 30 µM (Figure 4C). Compound 3 did not inhibit caspase-6 cleavage of recombinant Lamin A at 100 µM concentration.
Compound 3 was soaked into the crystal of the binary complex to yield a ternary complex of caspase-6/VEID/3 (see Table S4 for x-ray statistics). The caspase-6/VEID portion of the ternary structure is very similar to the caspase-6/VEID binary complex (Figure 5C). The unambiguous electron density for 3 reveals a unique simultaneous binding of substrate and inhibitor that explains the uncompetitive behavior of this series (Figure 5A, 5B). The carbonyl group of 3 makes a 3.1-A˚ hydrogen bond with the backbone NH of the P2 Ile of the bound VEID substrate surrogate. The dimethoxyphenyl ring of 3 sits above the oxanion hole created by the backbone NH group of Cys163; the 4-methoxy phenyl group displaces the water network around the His121-Cys163 catalytic dyad and the scissile bond. The furan ring does not make any specific interactions with the enzyme-substrate complex, and instead contributes to the active conformation of 3. The primary alcohol of 3 makes a hydrogen bond interaction with the P3 Glu of VEID and participates in a water-mediated interaction with Arg220 of the L3 loop of caspase-6. The benzonitrile ring of 3 overlaps with the S4 subsite and tucks under the L4 loop of caspase-6, which places the nitrile group close to the sidechains of His168 from the L2 loop and His219 from the L3 loop. The crystal structure does not suggest a specific interaction between caspase-6 and the nitrile group even though the presence of the 3-CN is crucial for high potency inhibition (manuscript in preparation). The slight difference in the conformation of the L4 loop in the ternary complex in comparison to the conformation in the binary complex is likely due to the benzonitrile ring interaction with residues at the tip of the L4 loop (Figure 5). In summary, the x-ray structure of compound 3 supports the specificity observed by enzymology; the compound recognizes both the caspase-6 enzyme and the VEID substrate. The x-ray structure lacks the Rh110 dye, indicating that compound 3 can bind to the VEID/caspase-6 complex in the absence of a prime-side dye.

Confirmation and Characterization of Ternary Complex Binding using Surface Plasmon Resonance (SPR)

Given that the affinity of compound 3 depends on the peptide sequence and presence of prime-side dye, an SPR-based assay was developed to characterize the binding affinity of 3 to catalytically dead (C163A mutation) as well as apo- and peptide inhibitor-bound forms of caspase-6. C163A-caspase-6 and Apo-caspase-6 were captured to different flow cells on a biosensor chip. One apo-caspase-6 surface was maintained in the apo-state while another was saturated with 20 μM Z-VEID-fluoromethyl ketone (Z-VEID-FMK) to produce the same binary Z-VEID/caspase-6 complex observed in X-ray crystallography. VEID-AMC (10 μM), (VEID)₂R110 (10 μM) and 3 (1 μM) were injected alone or in combination over all three surfaces (Figure 6A). Minimal binding was observed with VEID-AMC across all proteins while more (VEID)₂R110 bound to the C163A-caspase-6, consistent with substrate binding but inability of the catalytically dead caspase-6 to convert substrate to products. The greater degree in binding observed with (VEID)₂R110 versus VEID-AMC to the C163A-caspase-6 surface is likely attributable to the RM1 dye, indicating that compound 3 can bind to the VEID/caspase-6 complex in the absence of a prime-side dye.

Structural Characterization of Compound 3 Bound to Z-VEID/caspase-6

In order to elucidate the molecular details of the uncompetitive MOI, we sought to determine the crystal structure of the ternary caspase-6/substrate/3 complex. We first generated a binary complex of caspase-6 with a substrate surrogate covalently bound to the catalytic cysteine (Cys163) by incubating active caspase-6 with a covalent inhibitor (benzyloxycarbonyl (Z)-VEID-tetrafluorophenoxymethyl ketone). We observed that this inhibitor makes essentially the same interactions as previous reports of bound peptides with minor differences likely due to the additional methylene linker of this warhead compared to the aldehyde warhead used in other studies [6] (Figure 5).

Figure 4. Compound 3 inhibition of caspase-6 is dependent on the substrate’s amino acid sequence and the P1’ character of the substrate. (A) Concentration-response analysis of compound 3 against caspase-6 cleavage of divalent R110-containing substrates with VEID (black), DEVD (red), IETD (blue) or WEHD (green) amino acid tetrapeptides. Each assay was performed using substrate concentrations within 3-fold of the Kmapparent. (B) Concentration-response analysis of compound 3 against caspase-6 cleavage of monovalent VEID-based substrates with R110 (black) or AMC (blue) fluorophores conjugated to the C-terminal aspartate residue. (C) The indicated concentration of compound 3 or VEID-CHO was incubated with caspase-6 and GST-Lamin A prior to detection of cleaved Lamin A by western blotting. Only VEID-CHO was capable of inhibiting caspase-6 cleavage of recombinant Lamin A. Concentration response curves were generated in duplicate and represent 1 of at least 3 experiments with similar results. Each curve is normalized to zero and 100% based on no cleavage of recombinant Lamin A. Concentration response curves were captured to different flow cells on a biosensor chip. One apo-caspase-6 surface was maintained in the apo-state while another was saturated with 20 μM Z-VEID-fluoromethyl ketone (Z-VEID-FMK) to produce the same binary Z-VEID/caspase-6 complex observed in X-ray crystallography. VEID-AMC (10 μM), (VEID)₂R110 (10 μM) and 3 (1 μM) were injected alone or in combination over all three surfaces (Figure 6A). Minimal binding was observed with VEID-AMC across all proteins while more (VEID)₂R110 bound to the C163A-caspase-6, consistent with substrate binding but inability of the catalytically dead caspase-6 to convert substrate to products. The greater degree in binding observed with (VEID)₂R110 versus VEID-AMC to the C163A-caspase-6 surface is likely attributable to the RM1 dye, indicating that compound 3 can bind to the VEID/caspase-6 complex in the absence of a prime-side dye.
to the larger molecular weight of the divalent substrate combined with the higher concentration of substrate relative to $K_{\text{m,app}}$. The binding of 3 was only detected to the VEID blocked surface and was not modulated by the addition of VEID-AMC or \((\text{VEID})_2\text{R}110\) substrates, as expected due to blockage of the peptide binding site by VEID-FMK. However, the apo-caspase-6 and C163A-caspase-6 surfaces show a dramatically larger response when co-injected with \((\text{VEID})_2\text{R}110\) and 3 compared to injection of 3 itself, directly confirming the uncompetitive-binding mode of the interaction. Qualitatively, the data indicate a significantly higher affinity of these two interactions than 3+\((\text{VEID})_2\text{R}110\) with VEID-blocked caspase-6. The clearly slower off-rate can be fit to generate an apparent $K_D$ of $\sim$200 nM which represents the dissociation of both the compound and substrate. The same increase in response and apparent affinity improvement is not observed when 3 is co-injected with VEID-AMC, confirming the importance of the rhodamine-containing substrate for high-affinity binding and inhibition.

We observed very weak binding of 3 to apo-caspase-6 ($K_D = 192 \mu M$) while binding to the covalent VEID/caspase-6 complex demonstrated saturable 1:1 binding and a two-log improvement in the $K_D$ to 1.3 $\mu M$ (Figure 6B and 6C). These observations are consistent with compound binding being uncompetitive with respect to the peptide substrate. The difference between this $K_D$ and the enzymatic $IC_{50}$ values (11 nM for VEID-R110, 14 $\mu M$ for VEID-AMC) can be attributed to: 1) Use of fully VEID-saturated caspase-6 in the SPR experiments whereas the enzyme assays use cleavable substrates at a concentration equal to their $K_{\text{m,app}}$; 2) binding to the stable acyl-enzyme complex present in the SPR experiment versus the tetrahedral intermediate in the enzyme assays, and/or 3) occupation of the prime-side pocket with fluorophore in the enzyme assays. In any event, these data show that the presence of a P1’ fluorophore is not required for binding of compound 3 to VEID/caspase-6, but the presence and character of this fluorophore directly leads to additional compound-substrate interactions that modulate binding affinity.

**Discussion**

Our search for caspase-6 inhibitors led to the identification of a highly selective molecule that inhibits the enzyme via a novel mechanism not previously described for any of the caspases. Although it has recently been demonstrated for another cysteine protease that the acyl-enzyme intermediate is the primary resting state during the catalytic cycle [28], stabilization of this intermediate by 3 can be ruled out as the sole mechanism of inhibition, since no fluorophore dependence would be expected if this were the case. Therefore, there are two possible mechanisms by which these inhibitors may prevent cleavage of substrate: 1) stabilization of the Michaelis complex or 2) stabilization of the tetrahedral intermediate. To gain further structural insight into these possibilities we developed two models of the caspase-6/VEID-R110/3 ternary complex, one with unbound substrate to represent the Michaelis complex and one with substrate covalently bound to illustrate the tetrahedral intermediate. First, a model for the covalently bound tetrahedral intermediate was constructed by the covalent docking of a truncated substrate model to the caspase-6/3 complex followed by attachment of the R110 fluorophore (Figure 7B). This complex was then refined using Prime (Prime, version 2.2, Schrodinger, LLC, New York, NY, 2010) and MacroModel (MacroModel, version 9.8, Schrodinger, LLC, New York, NY, 2010). The Michaelis complex model was derived by breaking the cysteine-substrate bond in the covalent model and performing a constrained optimization of the complex where the inhibitor, substrate and catalytic dyad residues were permitted to move freely (Figure 7A) (details in Experimental Procedures S1). Both models provided low energy structures with plausible intermolecular contacts. Our existing data suggest that both
mechanisms – binding to the ternary complex and to the tetrahedral intermediate – are important.

With respect to MOI scenario #1, we observe cooperative binding of 3 with (VEID)\textsubscript{2}R110 or VEID-AMC to catalytically-dead (Cys163Ala) caspase-6 by SPR (Figure 6A). This result indicates that the 3/Michaelis complex can form, but it does not speak to whether 3 is able to prevent progress of the reaction, as would be required for inhibition. If 3 does indeed stabilize this complex to prevent formation of the tetrahedral intermediate, a possible mechanism is that 3 perturbs the oxyanion hole, inhibiting creation of the electrophilic carbonyl needed for attack. With respect to MOI scenario #2, our model also suggests that 3 could bind to the tetrahedral intermediate formed by addition of Cys163 to the amide bond (Figure 7B). We observe by x-ray crystallography that the dimethoxy phenyl ring of 3 disrupts the water network around the catalytic His121. Thus it is possible that if 3 prevents collapse of the tetrahedral intermediate, it could do so by perturbing the local environment around this key residue, preventing it from acting as the general acid. Although we are unable to isolate and quantify the binding interactions of 3 to the tetrahedral intermediate, it is noteworthy that the measured affinities of 3 to the Michaelis complex (\textasciitilde 200 nM by SPR) and acyl enzyme (1.3 \textmu M by SPR) are both weaker than the potency determined in enzymatic assays (11 nM IC\textsubscript{50}). We speculate that binding of 3 to the tetrahedral intermediate is the favored enzyme/substrate complex leading to potent inhibition.

An unexpected feature of this inhibitor is the 2–3 orders of magnitude difference in inhibitory potency depending on the fluorophore employed in enzymatic assays, and the apparent lack of activity when fluorophore-free substrates are utilized. The computational models suggest one possible explanation for this difference, namely a polarized CH-π interaction between the para-methoxy group of 3 and the face of the orthogonal phenyl ring of the R110 dye, an interaction that is not possible with AMC-based substrates or substrates lacking a dye (e.g. native protein substrates) (Figure 7C). The importance of such CH-π interactions has been noted previously [29]. Furthermore, there appears to be either an edge-face or π-stack interaction between the phenyl ring of the inhibitor and the fluorophore aromatic ring. The remaining interaction energy difference can be explained by displacement of waters by the two extra rings of the R110, and/or additional hydrophobic interactions between the extra two rings of R110 and the protein. All of these interactions would be absent in a peptide substrate lacking a fluorophore at the P1' position. It is known from studies on caspase-3 that prime side interactions can lead to a significant increase in inhibitory potency; for instance, the addition of a benzoxazole moiety on the prime side of the Ac-DEVD\textsubscript{a}-ketoaldehyde peptide inhibitor increases the potency \textasciitilde300-fold against caspase-3 [30]. As for the inability of 3 to inhibit Lamin A cleavage, the presence of substrate residues more distal to the scissile bond (P5–P8) may alter the general conformation of the inhibitor binding site to disrupt the key L2–L4 interactions observed in Figure 5B. The importance of P5 for caspase-2 substrate recognition and catalysis has been described [31] and we speculate that the inhibitor binding site defined here may be altered by similar enzyme-substrate interactions.

Figure 6. SPR detection of 3 binding to multiple caspase-6 surfaces confirms uncompetitive binding mode. (A) Catalytically inactive caspase-6 (green), apo-caspase-6 (blue) and caspase-6 saturated with VEID-FMK inhibitor (purple) were captured to chip surfaces and exposed to VEID-AMC, (VEID)\textsubscript{2}R110 and/or 3 to qualitatively monitor binding. Cooperative binding of 3 and (VEID)\textsubscript{2}R110 to C163 caspase-6 illustrate formation of the Michaelis-Menten complex. (B) Sensograms representing injections of escalating concentrations of 3 over VEID-FMK inhibitor-blocked caspase-6 surface (black). The inset represents similar injections of 3 over an unblocked apo-caspase-6 surface (blue). (C) Concentration-response analysis of data from (B) when compound 3 was injected over VEID-blocked caspase-6 surface (black) and apo-caspase-6 (blue) surfaces. doi:10.1371/journal.pone.0050864.g006
This class of inhibitors also shows sensitivity to the peptide sequence of the substrate, and unprecedented selectivity for caspase-6. To better understand this selectivity profile, we superposed the caspase-3/DEVD coordinates onto the caspase-6/VEID/3 ternary structure (Figure S3). Three residues lining the binding site of 3 provide a structural rationale for the selectivity of these inhibitors (Cys264 and Ala269 in the L4 loop and His209 in the L3 loop); we believe that Ala269 is the primary driver of caspase selectivity (amino acids depicted in Figure 5C). Ala269 is Phe256 in caspase-3 and Phe282 in caspase-7. These larger residues would hinder compound binding by clashing with the benzyl side chain of all inhibitors from this series. Our models also explain the substrate peptide sequence sensitivity of these inhibitors. The smaller Val residue in the substrate (DEVD)_{2}R110 would produce a weaker hydrophobic interaction between the substrate and the benzyl side chain, while the larger Trp and His residues in the substrate (WEHD)_{2}R110 would prevent inhibitor binding by clashing with the inhibitor side chain.

The substrate-dependent variation in potency minimizes the utility of these inhibitors as tools to understand target biology. This finding may also suggest that peptide surrogates used in biochemical assays have potential to contribute to misleading SAR for other series of inhibitors. This phenomenon is not specific to caspase-6. A common assay system used to profile the activity of the histone deacetylase enzymes also incorporates a proximal fluorophore attached to the C-terminus of a tetrapeptide. The crystal structure of this Arg-His-Lys-Lys-Coumarin substrate with HDAC8 illustrates direct interactions of the fluorophore with amino acid residue side chains [32]. Several reports make claim that SIRT activation by Resveratrol is an artifact of this fluorogenic assay [33,34], although follow up work confirms the original findings [35]. Thus, it is advised that a detailed mechanistic characterization of hits, as described here, be performed early in the triage stage of lead identification campaigns, particularly when inhibitors with unusual mechanisms are found.

In summary, the mechanistic and structural information described here explains the selective and substrate-specific inhibition of caspase-6 by a novel series of inhibitors. Uncompetitive inhibition is a proven strategy for other targets including MEK1/2 [36–38] and IMPDH [39,40] but because these compounds recognize a specific substrate-enzyme complex, they do not potently inhibit cleavage of other more physiologically relevant substrates. These particular inhibitors provide new insight into caspase selectivity, a topic of significant importance in drug discovery. This mechanism of uncompetitive inhibition is unique.
for any caspase family member and suggests that the discovery of inhibitors of specific, biologically relevant, enzyme-substrate complexes may be achievable. The observed binding of 3 to the acyl-enzyme when no fluorophore occupies the prime side (Figure 5 and Figure 6) suggests that elaboration of this series could lead to biologically relevant caspase-6 inhibitors. The work described herein provides a template for identification of uncompetitive caspase inhibitors as well as effective triage strategies of lead matter with novel mechanisms.

Supporting Information

Figure S1 Double-reciprocal Lineweaver-Burke plot of compound 3 with (VEID)₂R110 substrate showing uncompetitive MOI. Initial reaction velocities from nonlinear Michaelis-Menten kinetic experiment shown in Figure 3A was transformed to linear analysis for visualization. (TIF)

Figure S2 Kinetic caspase-6 enzymatic studies with compound 3 show uncompetitive mechanism of inhibition with (DEVD)₂R110 and VEID-AMC substrates. (A) The initial enzyme velocity of caspase-6 was plotted against the indicated concentration of (DEVD)₂R110 substrate in the presence of 0 nM (DMSO-black), 30 nM (red), 100 nM (orange), 300 nM (green), 1,000 nM (blue), 3,000 nM (purple) or 10,000 nM (pink) compound 3. (B) The initial enzyme velocity of caspase-6 was plotted against the indicated concentration of VEID-AMC substrate in the presence of 0 µM (DMSO-black), 1.6 µM (red), 3.1 µM (orange), 6.3 µM (green), 12 µM (blue), 25 µM (purple) or 50 µM (pink) compound 3. Experiments were performed with single points and represent 1 of at least 2 experiments with similar results. Enzyme velocity is normalized to zero and 100% based on no enzyme or DMSO, respectively. (TIF)

Figure S3 Structural comparison of the caspase-6/3 ternary complex reveals the structural basis of the exquisite caspase selectivity of this series of compounds. Superposition of the caspase-3/DEVD binary complex (2DKO) (light grey) onto the structure of the caspase-6/VEID/3 ternary complex (light blue). The three residue differences that would reduce the affinity of 3 for caspase-3 are highlighted in violet and numbered. 1 = Ala in caspase-6 and Phe in caspase-3 and caspase-7; 2 = Cys in caspase-6 and Ser in caspase-3 and caspase-7; 3 = His caspase-6 and Thr in caspase-3 and caspase-7. (TIFF)

Table S1 Kinetic rate constants and enzymatic reaction conditions for Caspases-3, -6 and -7.

Table S2 Potency of VEID-CHO and compound 3 against Caspase-3, -6 and -7 cleavage of divergent rhodamine substrates.

Table S3 Michaelis-Menten constants for (VEID)₂R110 with compound 3.

Table S4 Data Collection and Refinement of Compound 3 Complex.

Experimental Procedures S1 Supplemental Methods.

Acknowledgments

The authors wish to thank Dennis Wolan and Peter Lee at UCSF for assistance with protein expression, and Yvonne Franke and Krista Bowman at Genentech for cloning and expression of caspases.

Author Contributions

Conceived and designed the experiments: CEH KEA BB ARR MRA. Performed the experiments: CEH KEA BB AMG RNH K. Shah K. Stanger YT JM MS FC BRH ARR MRA. Contributed reagents/materials/analysis tools: PG ZZ MG JHC ENM. Performed the data analysis: CEH KEA BB AMG RNH K. Shah K. Stanger YT JM MS FC BRH ARR MRA. Contributed reagents/materials/analysis tools: PG ZZ MG JHC ENM. Wrote the paper: CEH JM MRA FC BRH AMG PG. Led the project team: JF JWL ARR MRA.

References

1. Earnshaw WC, Martins LM, Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68: 383–424.
2. Li J, Yuan J (2008) Caspases in apoptosis and beyond. Oncogene 27: 6194–6206.
3. Boatright KM, Salvesen GS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725–731.
4. Klaiman G, Champagne N, LeBlanc AC (2009) Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293 cells. Biochim Biophys Acta 1793: 592–601.
5. Salvesen GS, Doci VM (1999) Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A 96: 10964–10967.
6. Wang XJ, Cao Q, Liu X, Wang KT, Mi W, et al. (2010) Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation. EMBO Rep 11: 841–847.
7. Fuertes-Pio P, Salvesen GS (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384: 201–232.
8. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, et al. (1999) Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395–406.
9. Mahnus S, Trinidad JC, Barkan DT, Sali A, Burlingame AL, et al. (2008) Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini. Cell 134: 866–876.
10. Graham RK, Deng Y, Carroll J, Vaid K, Cowan G, et al. (2010) Cleavage at the 506 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci 30: 13019–13029.
11. Nikolov A, McLaughlin T, O’Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981–989.
12. Albrecht S, Bourdeau M, Bennett D, Mudson EJ, Bhattacharjee M, et al. (2007) Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 170: 1200–1209.
13. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, et al. (2004) Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease. Am J Pathol 165: 523–531.
14. Pereira NA, Song Z (2008) Some commonly used caspase substrates and inhibitors lack the specificity required to monitor individual caspase activity. Biochem Biophys Res Commun 377: 873–877.
15. Leyva MJ, Dejacofo M, Kaltenbach LS, Hokomb J, Zhang N, et al. (2010) Identification and evaluation of small molecule pan-caspase inhibitors in Huntington’s disease models. Chem Biol 17: 1189–1200.
16. Drag M, Salvesen GS (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9: 690–701.
17. Groebe DR (2009) In search of negative allosteric modulators of biological targets. Drug Discov Today 14: 41–49.
18. Hardy JA, Larr J, Nguyen JT, O’Brien T, Wells JA (2004) Discovery of an allosteric site in the caspases. Proc Natl Acad Sci U S A 101: 12461–12466.
19. Scheer JM, Romanowski MJ, Wells JA (2006) A common allosteric site and mechanism in caspases. Proc Natl Acad Sci U S A 103: 7595–7600.
20. Orwonski Z, Minor W (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode; Carter CW, Sweet, R.M., editor. New York: Academic Press.
21. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213–221.
23. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126–2132.
24. Giannetti AM (2011) From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. Methods Enzymol 493: 169–210.
25. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10: 464–469.
26. Takahashi A, Alnemri ES, Lazebnik YA, Fernandez-Alnemri T, Litwack G, et al. (1996) Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci U S A 93: 8393–8400.
27. Mintzer R, Ramaswamy S, Shah K, Hannoush RN, Ponnaiy CD, et al. (2012) A whole cell assay to measure caspase-6 activity by detecting cleavage of lamin a/c. PLoS One 7: e36376.
28. Schneck JL, Villa JP, McDevitt P, McQueney MS, Thrall SH, et al. (2008) Chemical mechanism of a cysteine protease, cathepsin C, as revealed by integration of both steady-state and pre-steady-state solvent kinetic isotope effects. Biochemistry 47: 8697–8710.
29. Pantgrahi SK, Desiraju GR (2007) Strong and weak hydrogen bonds in the protein-ligand interface. Proteins 67: 128–141.
30. Schmidt MF, El-Dahshan A, Keller S, Rademann J (2009) Selective identification of cooperatively binding fragments in a high-throughput ligation assay enables development of a picomolar caspase-3 inhibitor. Angew Chem Int Ed Engl 48: 6346–6349.
31. Tang Y, Wells JA, Arkin MR (2011) Structural and enzymatic insights into caspase-2 protein substrate recognition and catalysis. J Biol Chem 286: 34147–34154.
32. Vannini A, Velpari G, Gallinari P, Jones P, Mattu M, et al. (2007) Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep 8: 879–884.
33. Behr D, Wu J, Camme S, Kim KW, Lu SC, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619–624.
34. Pacholec M, Bleasdale JE, Chrunky B, Cunningham D, Flynn D, et al. (2010) SIRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340–8351.
35. Dai H, Kastigian L, Carney D, Case A, Conaidine T, et al. (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285: 32695–32703.
36. Ohren JF, Chen H, Pavlovski A, Whitehead G, Zhang E, et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192–1197.
37. Scholz-Leopold JS, Dudley DT, Herrera R, Van Baelcke K, Wåland A, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810–816.
38. VanScoy WS, Heldgate GA, Sullivan JE, Ward WH (2008) Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. Biochemistry 47: 5017–5027.
39. Hedstrom L, Wang CC (1990) Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism. Biochemistry 29: 849–854.
40. Sinchak MD, Fleming MA, Futer O, Rayback SA, Chambers SP, et al. (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85: 921–930.